Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/28/2025 | $23.00 | Buy | Rodman & Renshaw |
| 10/21/2024 | $20.00 | Buy | Alliance Global Partners |
| 9/27/2024 | $18.00 | Outperform | Raymond James |
| 8/22/2024 | $22.00 | Sector Outperform | Scotiabank |
| 6/1/2023 | $16.00 | Outperform | Robert W. Baird |
| 5/24/2022 | $14.00 → $7.00 | Buy → Neutral | B. Riley Securities |
| 1/24/2022 | $32.00 → $20.00 | Buy | B. Riley Securities |
| 7/7/2021 | $32.00 → $42.00 | Buy | Maxim Group |
DEFA14A - Inmune Bio, Inc. (0001711754) (Filer)
DEF 14A - Inmune Bio, Inc. (0001711754) (Filer)
8-K - Inmune Bio, Inc. (0001711754) (Filer)
4 - Inmune Bio, Inc. (0001711754) (Issuer)
4 - Inmune Bio, Inc. (0001711754) (Issuer)
4 - Inmune Bio, Inc. (0001711754) (Issuer)
Recently, on June 26, 2024, Director Juda Scott bought $36,350 worth of shares (5,000 units at $7.27) (SEC Form 4) in INmune Bio Inc. This insider purchase is significant as it indicates confidence from someone within the company towards its future growth prospects. It's interesting to note that this purchase by Juda Scott follows a series of transactions by other insiders in the company. For example, Moss David J bought $149,993 worth of shares (18,028 units at $8.32) on April 24, 2024, increasing direct ownership by 1% to 1,268,179 units. This demonstrates a consistent trend of insider buying within the organization. Looking back at previous transactions, on May 16, 2024, several key ins
4 - Inmune Bio, Inc. (0001711754) (Issuer)
4 - Inmune Bio, Inc. (0001711754) (Issuer)
4 - Inmune Bio, Inc. (0001711754) (Issuer)
Boca Raton, Florida, May 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company, is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion
DURHAM, N.C., Nov. 15, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced the appointment of Dr. Ed Baracchini as chairman of the Company's board of directors. "As a member of the CoImmune board of directors, Dr. Baracchini has provided strong counsel and guidance on many important issues in corporate development and strategy," stated Dr. Charles Nicolette, chief executive officer. "In his new role as chairman, his depth of experience in both biotechnology and fundraising will provide new levels of insight and guidance as we seek to advance our novel pipeline o
SC 13G - Inmune Bio, Inc. (0001711754) (Subject)
SC 13G/A - Inmune Bio, Inc. (0001711754) (Subject)
SC 13G - Inmune Bio, Inc. (0001711754) (Subject)
Rodman & Renshaw initiated coverage of INmune Bio with a rating of Buy and set a new price target of $23.00
Alliance Global Partners initiated coverage of INmune Bio with a rating of Buy and set a new price target of $20.00
Raymond James initiated coverage of INmune Bio with a rating of Outperform and set a new price target of $18.00
Boca Raton, Florida, US, April 16, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announced a major intellectual property milestone with respect to its next-generation mesenchymal stromal cell (MSC) product, CORDStrom™. The United States Patent and Trademark Office (USPTO), acting as the International Search Authority, has issued a favorable written opinion on all claims in INmune Bio's international patent application PCT/US25/17028, titled "THERAPEUTIC COMPOSITIONS COMPRISING POOLED, CULTURE-EXPANDED HUMAN UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS." The w
Stevenage, UK, and Boca Raton, Florida, US, April 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system has partnered with the Cell and Gene Therapy Catapult (CGT Catapult) to establish large-scale, commercial-ready manufacturing for its cell therapy platforms. CGT Catapult is an independent technology and innovation organization specializing in the advancement of the cell and gene therapy industry. It was established by and works in partnership with Innovate UK. INmune Bio's therapies harness the innate immune system, the body's first line of defense, to treat diseases incl
MINDFuL Phase II Blinded, Randomized, Placebo-Controlled Data Anticipated June 2025 Boca Raton, Florida, April 01, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, is presenting a poster at the annual International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders taking place in Vienna, Austria April 1-5 2025. AD/PD is the largest Alzheimer's conference in Europe. The poster details the demographics and biomarker status of patients at the time of enrollment in the MINDFul Phase II
BOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the year ended December 31, 2024 and provides a business update. Full Year 2024 and Recent Corporate Highlights DN-TNF Platform Highlights (XPro1595, XPro™): Announced completion of enrollment for its Phase 2 trial on Friday, 27 September, 2024. This global, blinded, randomized Phase 2 trial (the "AD02 trial") is focused on patients with Early Alzheimer's Disease (AD) and biomarkers of elevated n
Boca Raton, Florida, March 24, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company, today announced that it will host a conference call on Thursday, March 27, 2025, at 4:30pm EDT to discuss results for its quarter ended December 31, 2024, and to provide a corporate update. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Third Quarter Conference Call when reaching the operator. Date: March 27, 2025 Time: 4:30 PM Eastern Time Participant Dial-in: 1-800-225-9448 or 1-203-518-9708 Conference ID: INMUNE A li
BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2024 and provides a business update. Q3 2024 and Recent Corporate Highlights DN-TNF Platform Highlights (XPro™): Announced completion enrollment for its Phase 2 Alzheimer's Disease ("AD") trial on Friday, 27 September. This global, blinded, randomized Phase 2 trial (the "AD02 trial") is focused on patients with Early AD and biomarkers of elevated neuroinflammation.